|
|
 |
|
Viewing report
|
|
|
|
Countering Generic and Biosimilar Threats
Cutting Edge Information, June 2010, Pages: 246
Generics currently account for more than 10% of all drug sales and 75% of prescriptions dispensed and generic manufacturers are challenging patents more than ever before. Against this relentless assault, brand managers must deploy a mix of near- and long-term strategies to protect their assets. Knowing that it’s never too late to defend their brands’ sales or even to create additional revenue streams, innovator companies draw on foresight and their ability to marshal both commercial and clinical resources — to maximize the effectiveness of these counter-generics strategies.
Countering Generic and Biosimilar Threats: Near-Term and Long-Term Strategies provides in-depth breakdowns of 12 counter-generics strategies, with projections that reveal which ones will be used between now and 2013. Nine brand profiles, representing a wide range of therapeutic areas, allow for quick comparison against other teams across the industry.
- Perfect your generics defense strategy: Implement the right tactics at the right time with investment, timing and ROI benchmarks. Adopt a manageable blend of high- and low-investment options, and optimize task forces to build and retain counter-generics expertise.
- Learn from real-world examples: See how other brand teams have overcome the same issues you’re facing. Access the lessons learned in dozens of recent case studies of major brands, and explore sales projections to complete the picture.
- Assemble the best defense for biosimilars: Prepare for biosimilar competition using detailed metrics for 11 biologic brands. Quantify the financial threat posed by biosimilars, and consult strategies for mitigating these threats including US-specific options, which are crucial now that there is a US biosimilar pathway. See into the future of these drugs with analysis from industry leaders.
40+ Pharmaceutical and Biotech Companies Profiled in this report
Countering Generic and Biosimilar Threats’ six chapters contain benchmarks detailing task force structure and staffing, as well as timing, investments and ROI for counter-generics/biosimilars strategies. Throughout the report, data are frequently broken out into these company categories: Top 10, Top 25, Top 50 and Small.
Counter-generics strategies in the future (next 3 years) and recent past (last 3 years) - Counter-generics task force data:
- Number of companies with a dedicated task force
- Task force leadership, structure and staffing FTEs
- Functions represented on the task force
- Task force timelines in counter-generics planning
- Functions involved in counter-generics planning for companies that do not form task forces
Breakdown of individual strategies: (Includes, where appropriate: timing relative to patient expiration, investment, ROI/results, duration of planning and execution stages):
- Marketing and exclusivity extensions
- Defensive pricing and price changes
- Counter-promotion
- Litigation
- Citizen petitions
- Pediatric exclusivity
- Lifecycle management and line extensions
- New formulations
- Next-generation products
- New indications
- Combination products
- Market crossover tactics
- Authorized generics
- Generics subsidiary
- Rx-to-OTC switches
Biologics and biosimilars:
- Year and country of expected biosimilar competition for surveyed biologic brands
- Anticipated revenue loss to biosimilar competition
- Therapeutic areas for surveyed biologic brands
- Threat posed to biologic brands from changes in US biosimilars legislation
- Biologics’ counter-generics strategies
Company and brand counter-generics profiles:
- Basic company information (size, markets)
- Functions leading and participating in counter-generics effort
- Counter-generics staffing FTEs contributed by different functions
- Counter-generics timeline relative to patient expiration
- Specific strategies and tactics used across company’s brands
- Brand-specific profile:
- Annual sales before and after generics (where available)
- Year of patent expiry
- Brand’s markets by region
- Number of generics anticipated and currently competing
- Tactics and investments:
- Point at which planning began for specific tactics
- Time required to execute each tactic
- Investment (where available)
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Combating Generics: Counter-Generics Strategy, Tactics and Execution
Pharmaceutical Lifecycle Management: Strategy Selection and Execution
Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge
The Future of the Generics Industry: Opportunities, Threats and Key Trends
Generics Threats and Opportunities: Mounting an Effective Defense Strategy
Pharmaceutical Portfolio Management: Selecting Targets, Filling Pipelines and Preparing for Post-Launch Success
Biosimilar Drugs in Europe: Threat or Opportunity to Innovation?
Patent Protection Strategies: Maximising Product Revenues
The Impact of Generics on Pharmaceutical Growth Opportunities - A Growing Threat that Offers Future Opportunities
Biosimilars: Current Situation & Future Prospects, Worldwide
|
|
|
|
